Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer

Annals of Oncology

Volumn 21, Issue 10, 2010, Pages 1974-1981

  Cancello, G ^a   Maisonneuve, P ^b   Rotmensz, N ^b   Viale, G ^b,c   Mastropasqua, M G ^b   Pruneri, G ^b   Veronesi, P ^b,c   Torrisi, R ^a   Montagna, E ^a   Luini, A ^b   Intra, M ^b   Gentilini, O ^b   Ghisini, R ^a   Goldhirsch, A ^b   Colleoni, M ^a  

^a Department of Medicine   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Adjuvant therapy; Breast cancer; Prognostic features; Very young women

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; GONADORELIN DERIVATIVE; KI 67 ANTIGEN; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER INVASION; CANCER MORTALITY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RISK FACTOR; SENTINEL LYMPH NODE BIOPSY; TUMOR VOLUME;

EID: 77957110787     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq072     Document Type: Article

References (33)

1. Swanson GM, Lin CS. Survival patterns among younger women with breast cancer: the effects of age, race, stage, and treatment. J Natl Cancer Inst Monogr 1994; 16: 69-77.
2. Kroman N, Jensen MB, Wohlfahrt J et al. Factors influencing the effect of age on prognosis in breast cancer: population based study. BMJ 2000; 320: 474-478.
3. Albain KS, Allred DC, Clark GM. Breast cancer outcome and predictors of outcome: are there age differentials? J Natl Cancer Inst Monogr 1994; 16: 35-42.
4. Colleoni M, Rotmensz N, Robertson C et al. Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol 2002; 13: 273-279.
5. de la Rochefordiere A, Asselain B, Campana F et al. Age as prognostic factor in premenopausal breast carcinoma. Lancet 1993; 341: 1039-1043.
6. Han W, Kang SY. The Korean Breast Cancer Society. Relationship between age at diagnosis and outcome of premenopausal breast cancer age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer. Breast Cancer Res Treat 2010; 119(1): 193-200.
7. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003; 100: 8418-8423.
8. Oh DS, Troester MA, Usary J et al. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol 2006; 24: 1656-1664.
9. Rouzier R, Perou CM, Symmans WF et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11: 5678-5685.
10. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
11. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98: 10869-10874.
12. Cheang MC, Chia SK, Voduc D et al. Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer. J Natl Cancer Inst 2009; 101: 736-750.
13. Hugh J, Hanson J, Cheang MC et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 2009; 27: 1168-1176.
14. Viale G, Bosari S, Mazzarol G et al. Intraoperative examination of axillary sentinel lymph nodes in breast carcinoma patients. Cancer 1999; 85: 2433-2438.
15. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer: the value of histological grade in breast cancer. Histopathology 1991; 19: 403-410.
16. Rosen PP, Oberman HA. Tumors of the Mammary Gland. Washington DC: Armed Forces Institute of Pathology 1993.
17. Viale G, Regan MM, Mastropasqua MG et al. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst 2008; 100: 207-212.
18. Harvey JM, Clark GM, Osborne CK et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474-1481.
19. Colleoni M, Gelber S, Goldhirsch A et al. Tamoxifen after adjuvant chemotherapy for premenopausal patients with lymph-node positive breast cancer: International Breast Cancer Study Group Trial 13. J Clin Oncol 2006; 20: 1332-1341.
20. Veronesi U, Paganelli G, Viale G et al. A randomized comparison of sentinel node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003; 349: 546-553.
21. Goldhirsch A, Wood WC, Senn HJ et al. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 1995; 87: 1441-1445.
22. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 1998; 90: 1601-1608.
23. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 2001; 19: 3817-3827.
24. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16: 1569-1583.
25. Fisher B, Brown AM, Dimitrov NV et al. Two months of doxorubicincyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumours: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990; 8: 1483-1496.
26. Colleoni M, Litman HJ, Castiglione-Gertsch M et al. Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF. Br J Cancer 2002; 86: 1705-1714.
27. Carey LA, Perou CM, Livasy CA et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492-2502.
28. Bauer KR, Brown M, Cress RD et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007; 109: 1721-1728.
29. Goldhirsch A, Gelber RD, Yothers G et al. Adjuvant therapy for very young women with breast cancer: need for tailored treatments. J Natl Cancer Inst Monogr 2001; 30: 44-51.
30. Aebi S, Gelber S, Castiglione-Gertsch M et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 2000; 355: 1869-1874.
31. Ahn SH, Son BH, Kim SW et al. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea-a report from the Korean Breast Cancer Society. J Clin Oncol 2007; 25: 2360-2368.
32. Fisher B, Costantino J, Redmond C et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989; 320: 479-484.
33. Love RR, Duc NB, Havighurst TC et al. Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol 2003; 21: 453-457.